# BPC-157 TB-500 References: The Cited Wolverine Blend Literature

> BPC-157 TB-500 references: the full citation list behind the Wolverine blend digest — peer-reviewed studies and FDA sources, with DOIs and PubMed URLs.

Every quantitative claim on this site resolves here. Peer-reviewed studies and audited FDA sources, with DOIs and links.

## The BPC-157 TB-500 reference list

The BPC-157 TB-500 reference list below carries every study and source cited across this site, numbered to match the inline markers. The peptide-research citations are peer-reviewed primary studies and reviews; the regulatory entries (marked R1–R4) are FDA pages verified against the live source. Where a finding belongs to a single constituent, that is noted in the study itself — there is no combination study to cite, because none has been published [9]. The full citations appear in the [Wolverine blend references](/references) register on this page.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261-1270. https://pubmed.ncbi.nlm.nih.gov/1447300/
[6] Tokura Y, et al. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. https://pubmed.ncbi.nlm.nih.gov/20880960/
[7] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. https://pubmed.ncbi.nlm.nih.gov/22962027/
[9] Editorial synthesis: no peer-reviewed controlled study has administered BPC-157 and TB-500 in combination or defined a synergy ratio, dose, or endpoint. Basis: the absence of any combination study across the cited BPC-157 and thymosin beta-4 literature, including the 2025 BPC-157 systematic review (ref. 10), which makes no mention of TB-500 or combination use. https://pubmed.ncbi.nlm.nih.gov/40756949/
[10] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[11] Compositional and identity basis for the BPC-157 + TB-500 blend: BPC-157 is a 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV, ~1419.5 Da); TB-500 is the synthetic Ac-LKKTETQ heptapeptide (~889 Da), residues 17-23 of thymosin beta-4, and most efficacy data attributed to 'TB-500' were generated with full-length thymosin beta-4. The blend has no single CAS/MW and no standardized ratio. Identity of the TB-500 fragment established in Esposito S, et al., Drug Test Anal. 2012 (ref. 7); the actin-binding fragment relationship in Irobi E, et al., EMBO J. 2004 (ref. 3). https://pubmed.ncbi.nlm.nih.gov/22962027/
[12] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[13] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[14] Pharmacokinetic and dose-context basis: BPC-157 elimination half-life reported under 30 minutes in a rat/dog PK study, and rodent doses commonly expressed per body weight (frequently ~10 microg/kg; gastric-ulcer cytoprotection at 400-800 ng/kg). Thymosin beta-4 dose-response in a rat embolic-stroke model spanned 2-18 mg/kg intraperitoneal, with 18 mg/kg giving no benefit (non-monotonic). Compiled in the audited Wolverine research corpus (dosage_research_context); thymosin beta-4 stroke dose-response per Morris DC, et al., Neuroscience. https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+beta-4+embolic+stroke+dose
[15] World Anti-Doping Agency. The Prohibited List. BPC-157 is listed under category S0 (non-approved substances); thymosin beta-4 / TB-500 falls under prohibited peptide and tissue-repair categories. Prohibited at all times, in and out of competition. https://www.wada-ama.org/en/prohibited-list

---

An instructional scroll of the BPC-157 TB-500 literature, carved register by register and weighed against its sources, with no clinic in the record and nothing here to dispense.